Results 41 to 50 of about 68,932 (288)

Rapid Nongenomic Effects of Oestradiol on Gonadotrophin‐Releasing Hormone Neurones [PDF]

, 2012
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/89550/1/j.1365-2826.2011.02135.x ...
Abe, Abe, Abraham, Abraham, Christian, Christian, Christian, Christian, Christian, Christian, Christian, Chu, Chu, Clarke, DeFazio, Docke, Heldring, Herbison, Herbison, Hrabovszky, Hu, Kelly, Kelly, Kelly, Lagrange, Lalmansingh, Levin, Mendelsohn, Moenter, Moenter, Navarro, Nelson, Noel, Qiu, Revankar, Romano, Spergel, Sun, Suter, Temple, Terasawa, Toran-Allerand, Wintermantel, Woolley, Zhang, Zhang   +45 more
core   +1 more source

Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer

Therapeutic Advances in Urology, 2015
Objectives: Gonadotropin-releasing hormone agonists are widely used as androgen deprivation therapy in many men with locally advanced or metastatic prostate cancer. Gonadotropin-releasing hormone agonists are delivered by intramuscular injection every 1,
Thiery Lebret, Mathieu Rouanne, Oleg Hublarov, Viorel Jinga, Lidiya Petkova, Rumen Kotsev, Ioanel Sinescu, Pascale Dutailly   +7 more
doaj   +1 more source

The direct response of the gonads to cues of stress in a temperate songbird species is season-dependent. [PDF]

, 2013
The gonadotropin releasing hormone (GnRH) system in the hypothalamus is often considered the final point in integration of environmental cues as they pertain to the reproductive axis.
Bentley, George, Koh, Annie, McGuire, Nicolette   +2 more
core   +2 more sources

Effect of Endometrium Thickness on Clinical Outcomes in Luteal Phase Short-Acting GnRH-a Long Protocol and GnRH-Ant Protocol

Frontiers in Endocrinology, 2021
ObjectiveTo investigate the factors that influence luteal phase short-acting gonadotropin-releasing hormone agonist (GnRH-a) long protocol and GnRH-antagonist (GnRH-ant) protocol on pregnancy outcome and quantify the influence.
Jie Zhang, Yi-Fei Sun, Yue-Ming Xu, Bao-jun Shi, Yan Han, Zhuo-Ye Luo, Zhi-Ming Zhao, Gui-Min Hao, Bu-Lang Gao   +8 more
doaj   +1 more source

Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles [PDF]

, 2015
Background This secondary analysis aimed to identify predictors of low (<6 oocytes retrieved) and high ovarian response (>18 oocytes retrieved) in IVF patients undergoing controlled ovarian stimulation with corifollitropin alfa in a gonadotropin-
Nelson, Scott M., Oehninger, Sergio, Stegmann, Barbara J., Verweij, Pierre   +3 more
core   +1 more source

Functional Divergence of Glycoprotein Hormone Receptors [PDF]

, 2010
Two lamprey glycroprotein hormone receptors (lGpH-R I and II) highly similar with gnathostome GpH-Rs were cloned from sea lamprey testes and thyroid, respectively.
Freamat, Mihael, Sower, Stacia A.
core   +3 more sources

Direct evidence on the efficacy of GnRH agonist in recurrent steroid cell tumor-not otherwise specified

Gynecologic Oncology Reports, 2019
Background: Steroid cell tumor (SCT) not otherwise specified (NOS) is rare and recurrence and metastasis rarely occurs; therefore, reports regarding its treatment are limited.
Tadaharu Nakasone, Tomoko Nakamoto, Akiko Matsuzaki, Hiroshige Nakagami, Yoichi Aoki   +4 more
doaj   +1 more source

Medical Therapies for Uterine Fibroids - A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials [PDF]

, 2016
BACKGROUND: Uterine fibroids are common, often symptomatic and a third of women need repeated time off work. Consequently 25% to 50% of women with fibroids receive surgical treatment, namely myomectomy or hysterectomy.
A Armstrong, A Daniels, A Golan, A Lethaby, A Lieto, A Zimmermann, AJ Audebert, AJ Friedman, AJ Friedman, AJ Friedman, AJ Friedman, Andrew Horne, AR Williams, AR Williams, B Kroon, BJ Borah, CC Coddington, D De Aloysio, D Mavrelos, D Moher, DD Baird, DD Baird, E Roshdy, E Verspyck, E Zullo, ED Levens, EE Marsh, EK Arleo, EP Morris, ERC, A.D. Cardozo, F Parazzini, F Polatti, F Zullo, F Zullo, G Levy, G Orsini, G Salanti, GH Guyatt, GH Sayed, GS Carls, H Song, HH Bustos Lopez, Ian S. Fraser, J Balasch, J Donnez, J Donnez, J Donnez, J Gerris, J Higgins, J van de Ven, J van de Ven, J Wilkens, JB Engel, Jessica Vaughan, JH Segars, JL Esteve, JL Rutgers, K Chwalisz, K Fiscella, K Puri, KR Hodges, Kurinchi S. Gurusamy, L Deng, L Fedele, L Fedele, L Fedele, L Muzii, Lawrence M. J. Best, LJ Green, LK Nieman, M Bagaria, M De Falco, M Egger, M Engman, M Moshesh, M Rees, M Sayyah-Melli, M Tristan, MA Lumsden, ME Fernandez-Mentoli, ME Parsanezhad, MG Munro, MS Melli, N Biglia, N Johnson, N Varun, O Gregoriou, O Muneyyirci-Delale, O Sadan, P Vercellini, PG Moorman, R D'Anna, R Hudecek, R Seracchioli, RC Reinsch, RL Barbieri, RW Shaw, S Campo, S Constantini, S Jirecek, S Jo Varghese, S Palomba, S Palomba, S Palomba, S Palomba, S Palomba, S Palomba, S Palomba, S Palomba, S Palomba, SE Bulun, SL Myers, SS Lim, T Simsek, TG Stovall, TG Stovall, TG Stovall, Toby Richards, WD Schlaff, YB Baytur   +119 more
core   +4 more sources

Different Timing of Adjuvant Low Dose hCG and GnRH Agonist Trigger Protocol, in OHSS High-Risk Patient with Peak E2 Level <4000 pg/mL

Gynecology Obstetrics & Reproductive Medicine, 2020
OBJECTIVE: The aim of the study is to compare the live birth rates between 1,500 I.U. of Human chorionic gonadotropin at the time of Gonadotropin-releasing hormone agonist trigger day or 35-36 h later on the oocyte pick-up day, without affecting the ...
Emilija Zoran Petanovska Kostova, Velentina Sotirovska, Gligor Dimitrov, Snezana Stojkovska, Makjuli Hadzi Lega, Daniela Stojanovska, Nikoleta Stamenkovska, Liljana Simjanovska, Zoranco Petanovski   +8 more
doaj   +1 more source

Safety, Pharmacokinetic and Pharmacodynamic Evaluation of Teverelix for the Treatment of Hormone-Sensitive Advanced Prostate Cancer: Phase 2 Loading-Dose-Finding Studies

Medicina, 2023
Background and objectives: Teverelix drug product (DP) is a gonadotropin-releasing hormone antagonist in development for the treatment of patients with prostate cancer in whom androgen deprivation therapy is indicated. The aim of this paper is to present
Carol M. MacLean, Albertas Ulys, Feliksas Jankevičius, Žilvinas Saladžinskas, Steve van Os, Finn Larsen   +5 more
doaj   +1 more source